**Information to support the review of Annex A to the Minamata Convention**

|  |  |  |
| --- | --- | --- |
| **1. Category of mercury-added product[[1]](#footnote-1)** | Batteries  Switches and relays  Lamps  Cosmetics | Pesticides, biocides and topical antiseptics  Non-electronic measuring devices  Others *(Please specify:* *)* |
| **2. Further description of the product** (if any) |  | |
| **3. Information on the use of the product** |  | |
| **4. Information on the availability of mercury-free (or less-mercury) alternatives** |  | |
| **5.(i) Information on the technical feasibility of alternatives** |  | |
| **5.(ii) Information on the economic feasibility of alternatives** |  | |
| **6. Information on environmental and health risks and benefits of alternatives** |  | |
| **7. If any, additional information being submitted on mercury-added products pursuant to Article 4.4 of the Convention not addressed above (e.g. manufacture, general trade information, etc.)** |  | |
| **8. Other relevant information pursuant to Decision MC-3/1** |  | |
| **9. References** |  | |

**Information to support the review of Annex B to the Minamata Convention**

|  |  |
| --- | --- |
| **1. Category of manufacturing process in which mercury or mercury compounds are used** | Chlor-alkali production  Acetaldehyde production in which mercury or mercury compounds are used as a catalyst  Vinyl chloride monomer production  Sodium or Potassium Methylate or Ethylate  Production of polyurethane using mercury containing catalysts  Others *(Please specify: )* |
| **2. Further description of the process** (if any) |  |
| **3. Information on the manufacturing activities using the process** (incl. amount of mercury or mercury compounds used, production amount, etc.) |  |
| **4. Information on the availability of mercury-free (or less-mercury) alternatives** |  |
| **5.(i) Information on the technical feasibility of alternatives** |  |
| **5.(ii) Information on the economic feasibility of alternatives** |  |
| **6. Information on the environmental and health risks and benefits of alternatives** |  |
| **7. Other relevant information pursuant to Decision MC-3/1** |  |
| **8. References** |  |

1. Dental amalgam is subject to a separate intersessional process as specified in Decision MC-3/2. [↑](#footnote-ref-1)